UK Markets open in 3 hrs 30 mins

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
251.41+9.18 (+3.79%)
At close: 4:00PM EST
Sign in to post a message.
  • T
    Tony
    Big LEVEL on the daily chart mentioned in this publication on MRNA ..I am feeling good about this https://lussosnews.com/moderna-mrna-nearing-a-key-technical-level-heading-into-the-week/
  • N
    NY
    Morgan Stanley analyst Matthew Harrison thinks Moderna stock could jump 10% or more.
    Harrison expects Moderna to soon report positive phase 1 results for its experimental flu vaccine.
  • A
    Al
    $NVAX conversation
    A few days until several approvals —>SP more than $300.

    A must own stock in this week!!! :

    ““https://finance.yahoo.com/m/ec0dae6c-acb4-3aa9-822b-aa2e2a4019bb/moderna-pfizer-and-novavax.html””

    $NVAX $MRNA
  • J
    Joseph
    Can’t wait to see futures open tonight. This will be up big tomorrow no matter what, but if futures are in the red by 2_% or more than this will be up even more. Could get to $400 tomorrow, and if not then it’ll be very close
  • B
    BullFight-2020
    Are we ready for 400 tomorrow
  • T
    Titos
    New vaccine for Omicron may be ready in early 2022, says Moderna
  • b
    bill
    Bought 1,100 shares PM Friday at $293, but got scared and sold them at $335. Wish I woulda held them. I see $400 the next 2 days. Glta.
  • S
    Shannon
    Buckle up, Take off imminent!

    "Moderna Inc. Chief Medical Officer Paul Burton said he suspects the new omicron coronavirus variant may elude current vaccines and, if so, a reformulated shot could be available early next year. Moderna is testing the current vaccine against the new variant and studying two booster candidates."
  • 有一
    I hope under 400 in the premarket on Monday.
    I’d like to buy before it gets too high to buy.

    Last Friday 80% of the price increase was in the premarket.
  • N
    NY
    Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant-
    BusinessWire-
    Company announcing a new variant-specific vaccine candidate against Omicron (mRNA-1273.529).
  • g
    gregg
    Trending
  • K
    KEVIN ARTHUR
    Modena is gonna pop up to new all time highs based on boosters flu shot c-19 pipeline mfg capacity global presence and data supporting efficacy as best in world

    Congrats longs
  • K
    Kowch
    Moderna says an omicron variant vaccine could be ready in early 2022

    PUBLISHED SUN, NOV 28 2021 9:43 AM ESTUPDATED AN HOUR AGO

    Jessica Bursztynsky

    KEY POINTS

    Moderna's Chief Medical Officer Paul Burton said Sunday the vaccine maker could roll out a reformulated vaccine against the omicron coronavirus variant early next year.

    It's not clear whether new formulations will be needed, or if current Covid vaccinations will provide protection against the new variant that has begun to pop up around the globe.

    Omicron was classified as a "variant of concern" by the WHO last week.

    Moderna's Chief Medical Officer Paul Burton said Sunday the vaccine maker could roll out a reformulated vaccine against the omicron coronavirus variant early next year.
    It's not clear whether new formulations will be needed, or if current Covid vaccinations will provide protection against the new variant that has begun to spread around the globe.
    "We should know about the ability of the current vaccine to provide protection in the next couple of weeks, but the remarkable thing about the MRNA vaccines, Moderna platform is that we can move very fast," Burton said on BBC's "Andrew Marr Show."
    "If we have to make a brand new vaccine I think that's going to be early 2022 before that's really going to be available in large quantities," the Moderna chief added.
    Omicron has been classified as a "variant of concern" by the World Health Organization, meaning it is more contagious, more virulent or more skilled at evading public health measures, vaccines and therapeutics. The variant contains 30 mutations to the spike protein that allows the virus to enter the body. Officials have warned that many of these mutations could lead to increased antibody resistance and transmissibility, which could limit the effectiveness of existing Covid vaccines.
    The vaccine maker "mobilized hundreds" of workers starting early Thursday morning, on Thanksgiving, to start studying the new variant, the company said in a statement.
    Current vaccines could provide some protection, depending on how long ago a person was injected, Burton said. Still, he said unvaccinated people should get vaccinated or receive their booster shots, if eligible.

    Moderna says an omicron variant vaccine could be ready in early
  • A
    Austin
    Cash App lets you send and receive up to $1,000 within any 30-day period. You can increase these limits cash app hacks that work.
    Try The Free Offer Now | Get Ready to Earn $1000 for Free Just visited cash app giveaway. Visit: https://sites.google.com/view/getcashapprewards/home
  • D
    Drax
    Expectations for this week?
  • A
    Al
    CNN: The Omicron variant is a wake up alarm that the new mutant variants are on their ways!!

    $MRNA $NVAX
  • S
    Sinful Golddigger
    I have had 3 MRNA vaccinations. I will buy some stock on Monday
  • D
    Denise
    Price on Monday will be up at least 10-15%
  • Z
    Zheng
    So far, 10 countries reported Omicron cases. It spread more fast than people imaged. We may see another wave of COV19 in beginning of 2022. Moderna vaccine should play a big role in 2022 and its stock will be back $400 and may be break through $500 soon.
  • K
    Kowch
    The pandemic's latest twist makes these three stocks screaming buys 

    Moderna, Pfizer, and Novavax all enjoyed a sizable jump in their share prices during the holiday-shortened trading session on Friday thanks to their quick reaction to the omicron variant. Specifically, Moderna announced that it is working on an omicron-specific vaccine, as well a unique booster shot regimen, based on its currently authorized COVID-19 vaccine, that may provide a higher level of immune protection against this new variant.
    Pfizer, for its part, said that its BioNTech-partnered COVID-19 vaccine can easily be tailored to the omicron variant and be ready for use within 100-days -- that is, if the original version of its vaccine fails to provide adequate protection. Novavax also provided an update on its omicron vaccine strategy last Friday, with the biotech saying that it plans on having an omicron-specific shot ready for testing and manufacturing within the next few weeks.

    Why are these omicron-tailored vaccines a huge positive for their developers? The messenger RNA (mRNA) vaccines from Moderna and Pfizer/BioNTech both appeared to be on the back end of the commercial shelf lives prior to this news. As a result, Moderna's stock was in the midst of notable downward trend earlier this month. The sudden need for more potent booster shots and a potential variant-specific vaccine should keep Moderna's top line headed in the right direction in 2022, which ought to light a fire underneath the biotech's shares for the remainder of the year.
    While Pfizer's equity hasn't skipped a beat of late because of its oral coronavirus pill, the pharma giant now stands to possibly benefit from another year of exceptionally strong COVID-19 vaccine sales. Pfizer's stock, in turn, will probably continue to print ever-increasing record highs heading into 2022. 
    On the Novavax side of ledger, the biotech's shares are currently down by a whopping 31% from their 52-week highs. The vaccine specialist's shares have dipped in the back half of 2021 in response to manufacturing issues, regulatory delays, and a growing concern among investors that the company may have simply missed the boat.
    What's important to understand is that Novavax's COVID-19 vaccine is protein-based, which may appeal to a broad range of folks hesitant about cutting-edge mRNA vaccines. This new variant, therefore, ought to keep this latent demand for Novavax's alternative jab on the high side, as the company slowly completes the regulatory process in the all-important U.S. market.  

    In short, Moderna, Pfizer, and Novavax are all poised to benefit in a big way from their unique vaccine development capabilities, making their stocks exceedingly strong buys this week.